001     3496
005     20180208222108.0
024 7 _ |2 pmid
|a pmid:20665489
024 7 _ |2 DOI
|a 10.1007/s00339-009-5188-0
024 7 _ |2 WOS
|a WOS:000266372100005
024 7 _ |2 ISSN
|a 0947-8396
037 _ _ |a PreJuSER-3496
041 _ _ |a eng
082 _ _ |a 530
084 _ _ |2 WoS
|a Materials Science, Multidisciplinary
084 _ _ |2 WoS
|a Physics, Applied
100 1 _ |0 P:(DE-Juel1)132115
|a Gibbon, P.
|b 0
|u FZJ
245 _ _ |a Modelling and optimisation of femtosecond laser-produced K-alpha sources
260 _ _ |a Berlin
|b Springer
|c 2009
300 _ _ |a 23 - 31
336 7 _ |a Journal Article
|0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|0 0
|2 EndNote
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a article
|2 DRIVER
440 _ 0 |0 560
|a Applied Physics A
|v 96
|x 0947-8396
|y 1
500 _ _ |a This work was supported by the Deutsche Forschungsgemeinschaft (DFG grant-nos. GI 300/3-1, TE 190/6-1 and So 408/6-3) and the FLASH network.
520 _ _ |a The most reliable prognostic factor in colon cancer is the TNM classification. The objective of this study was to assess and compare the prognostic role of tumor-infiltrating lymphocytes (TILs) in stage II colon cancer.Immunohistochemistry was used to assess the density of TILs that were positive for cluster of differentiation 3 (CD3) (T-cell coreceptor), CD45 isoform RO (CD45RO) (protein tyrosine phosphatase), nuclear transcription factor forkhead box P3 (FOXP3), and CD25 (a type I transmembrane protein) according to tumor site (intraepithelial and stromal) in samples from 87 patients who had stage II colon cancer. These variables were evaluated for their association with histopathologic features along with overall survival (OS) and disease-free survival (DFS).Intraepithelial CD3-posititve (CD3+), CD45RO+, CD25+, and FOXP3+ TILs were associated significantly with better DFS (P = .049, P = .009, P = .013, and P = .001, respectively). The estimated 5-year OS rates for patients who had high-density CD45RO+ and FOXP3+ expression was 100% for both compared with 79.2% and 78.8% for patients who had low-density CD45RO+ and FOXP3+ expression (P = .017 and P = .040, respectively). A significant prognostic factor for both OS and DFS was high-density stromal CD45RO+ lymphocytic infiltration (OS: P = .031; relative risk [RR], 0.134; 95% confidence interval [CI], 0.015-1.164; DFS: P = .013; RR, 0.198; 95% CI, 0.055-0.710); whereas intraepithelial FOXP3+ expression was an independent prognostic factor for DFS (P = .032; RR, 0.108; 95% CI, 0.014-0.821).FOXP3+ and CD45RO+ TILs demonstrated independent prognostic significance for survival in the current investigation. These results may help to improve the prognostication of early stage colon cancer. Cancer 2010.
536 _ _ |0 G:(DE-Juel1)FUEK411
|2 G:(DE-HGF)
|a Scientific Computing
|c P41
|x 0
588 _ _ |a Dataset connected to Web of Science, Pubmed
650 _ 2 |2 MeSH
|a Adult
650 _ 2 |2 MeSH
|a Aged
650 _ 2 |2 MeSH
|a Colonic Neoplasms: immunology
650 _ 2 |2 MeSH
|a Colonic Neoplasms: pathology
650 _ 2 |2 MeSH
|a Disease-Free Survival
650 _ 2 |2 MeSH
|a Female
650 _ 2 |2 MeSH
|a Humans
650 _ 2 |2 MeSH
|a Immunohistochemistry
650 _ 2 |2 MeSH
|a Lymphocytes, Tumor-Infiltrating: immunology
650 _ 2 |2 MeSH
|a Male
650 _ 2 |2 MeSH
|a Middle Aged
650 _ 2 |2 MeSH
|a Neoplasm Invasiveness
650 _ 2 |2 MeSH
|a Prognosis
650 _ 7 |2 WoSType
|a J
700 1 _ |0 P:(DE-Juel1)VDB84133
|a Masek, M.
|b 1
|u FZJ
700 1 _ |0 P:(DE-HGF)0
|a Teubner, U.
|b 2
700 1 _ |0 P:(DE-HGF)0
|a Lu, W.
|b 3
700 1 _ |0 P:(DE-HGF)0
|a Nicoul, M.
|b 4
700 1 _ |0 P:(DE-HGF)0
|a Shymanovich, A.
|b 5
700 1 _ |0 P:(DE-HGF)0
|a Tarasevitch, A.
|b 6
700 1 _ |0 P:(DE-HGF)0
|a Zhou, P.
|b 7
700 1 _ |0 P:(DE-HGF)0
|a Sokolowski-Tinten, K.
|b 8
700 1 _ |0 P:(DE-HGF)0
|a von der Linde, D.
|b 9
773 _ _ |0 PERI:(DE-600)1398311-8
|a 10.1007/s00339-009-5188-0
|g Vol. 96, p. 23 - 31
|p 23 - 31
|q 96<23 - 31
|t Applied physics / A
|v 96
|x 0947-8396
|y 2009
856 7 _ |u http://dx.doi.org/10.1007/s00339-009-5188-0
909 C O |o oai:juser.fz-juelich.de:3496
|p VDB
913 1 _ |0 G:(DE-Juel1)FUEK411
|a DE-HGF
|b Schlüsseltechnologien
|k P41
|l Supercomputing
|v Scientific Computing
|x 0
914 1 _ |y 2009
915 _ _ |0 StatID:(DE-HGF)0010
|2 StatID
|a JCR/ISI refereed
915 _ _ |0 StatID:(DE-HGF)0100
|2 StatID
|a JCR
915 _ _ |0 StatID:(DE-HGF)0111
|2 StatID
|a WoS
|b Science Citation Index Expanded
915 _ _ |0 StatID:(DE-HGF)0150
|2 StatID
|a DBCoverage
|b Web of Science Core Collection
915 _ _ |0 StatID:(DE-HGF)0199
|2 StatID
|a DBCoverage
|b Thomson Reuters Master Journal List
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
920 1 _ |0 I:(DE-Juel1)JSC-20090406
|g JSC
|k JSC
|l Jülich Supercomputing Centre
|x 0
970 _ _ |a VDB:(DE-Juel1)109581
980 _ _ |a VDB
980 _ _ |a ConvertedRecord
980 _ _ |a journal
980 _ _ |a I:(DE-Juel1)JSC-20090406
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21